Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

Behavioural Brain Research

Volumn 293, Issue , 2015, Pages 96-106

  McClean, Paula L ^a   Jalewa, Jaishree ^b   Hölscher, Christian ^b  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Growth factor; Incretin; Insulin; LTP; Memory loss; Synaptic loss

Indexed keywords

GLUCOSE; LIRAGLUTIDE; SYNAPTOPHYSIN; AMYLOID PRECURSOR PROTEIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PRESENILIN 1;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; CELL ACTIVATION; CHRONIC DRUG ADMINISTRATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; GLUCOSE BLOOD LEVEL; HIPPOCAMPAL CA1 REGION; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MICROGLIA; MORRIS WATER MAZE TEST; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RECOGNITION; TASK PERFORMANCE; WILD TYPE; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; EXCITATORY POSTSYNAPTIC POTENTIAL; GENETICS; HIPPOCAMPUS; INFLAMMATION; MAZE TEST; MEMORY DISORDERS; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; INFLAMMATION; LIRAGLUTIDE; LONG-TERM POTENTIATION; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PATCH-CLAMP TECHNIQUES; PLAQUE, AMYLOID; PRESENILIN-1; RECOGNITION (PSYCHOLOGY);

EID: 84938150420     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.07.024     Document Type: Article

References (48)

1. Abbas T., Faivre E., Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 2009, 205:265-271.
2. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Ell P., Soderlund T., Foltynie T. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 2013, 123(6):2730-2736. 10.1172/JCI68295.
3. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Kahan J., Fmedsci P.E., Foltynie T. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's Disease. J. Parkinsons Dis. 2014, 4(3):337-344. 10.3233/JPD-140364.
4. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest. 2012, 122(4):1339-1353. 10.1172/JCI57256.
5. Bondolfi L., Calhoun M., Ermini F., Kuhn H.G., Wiederhold K.H., Walker L., Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci. 2002, 22(2):515-522.
6. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013, 17(6):819-837. 10.1016/j.cmet.2013.04.008.
7. Chen Y., Chad J.E., Wheal H.V. Synaptic release rather than failure in the conditioning pulse results in paired-pulse facilitation during minimal synaptic stimulation in the rat hippocampal CA1 neurones. Neurosci. Lett. 1996, 218(3):204-208.
8. Davies M.J., Kela R., Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes. Metab. 2011, 13(3):207-220. 10.1111/j.1463-1326.2010.01330.x.
9. EMA. (2013). Assessment report for GLP-1 based therapies.
10. Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S.B., Vang, K., Rungby, J. (2015). No Decline of Brain Glucose Metabolism in Alzheimer's Disease Patients Treated with Liraglutide. Poster presented at the American Diabetes Association, Boston, USA, 1309-P.
11. Gengler S., Hamilton A., Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One 2010, 5(3):e9764.
12. Hansen H.H., Fabricius K., Barkholt P., Niehoff M.L., Morley J.E., Jelsing J., Vrang N. The GLP -1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's Disease. J. Alzheimers Dis. 2015, 10.3233/JAD-143090.
13. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., Perry V.H. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73(10):768-774. 10.1212/WNL.0b013e3181b6bb95.
14. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2013, 221:31-41. 10.1530/JOE-13-0221.
15. Holscher C. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem. Soc. Trans. 2014, 42(2):593-599. 10.1042/BST20140016.
16. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13(1):33-38. 1471-2202-13-33[pii]. 10.1186/1471-2202-13-33.
17. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikstrom L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 2011, 650(1):249-255.
18. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001, 17(6):157-165.
19. Kelly P., McClean P.L., Ackermann M., Konerding M.A., Holscher C., Mitchell C.A. Restoration of CErebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with liraglutide. Microcirculation 2015, 22(2):133-145. 10.1111/micc.12186.
20. Kovacs D.M., Wasco W., Witherby J., Felsenstein K.M., Brunel F., Roeder R.G., Tanzi R.E. The upstream stimulatory factor functionally interacts with the Alzheimer amyloid beta-protein precursor gene. Hum. Mol. Genet. 1995, 4(9):1527-1533.
21. Lee Y.J., Han S.B., Nam S.Y., Oh K.W., Hong J.T. Inflammation and Alzheimer's disease. Arch. Pharm. Res. 2010, 33(10):1539-1556. 10.1007/s12272-010-1006-7.
22. Li Y., Tweedie D., Mattson M.P., Holloway H.W., Greig N.H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 2010, 113(6):1621-1631. 10.1111/j.1471-4159.2010.06731.x.
23. Long-Smith C.M., Manning S., McClean P.L., Coakley M.F., O'Halloran D.J., Holscher C., O'Neill C. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromol. Med. 2013, 15(1):102-114. 10.1007/s12017-012-8199-5.
24. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5(5):262-269.
25. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7):1187-1192.
26. McClean P., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
27. McClean P.L., Gault V.A., Harriott P., Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 2010, 630:158-162.
28. McClean P.L., Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014, 76(Pt A):57-67. 10.1016/j.neuropharm.2013.08.005.
29. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31(2):224-243.
30. Najem D., Bamji-Mirza M., Chang N., Liu Q.Y., Zhang W. Insulin resistance, neuroinflammation, and Alzheimer's disease. Rev. Neurosci. 2014, 10.1515/revneuro-2013-0050.
31. Ohara T., Doi Y., Ninomiya T., Hirakawa Y., Hata J., Iwaki T., Kiyohara Y. Glucose tolerance status and risk of dementia in the community: The Hisayama Study. Neurology 2011, 77(12):1126-1134. 77/12/1126 [pii]. 10.1212/WNL.0b013e31822f0435.
32. Ohtake N., Saito M., Eto M., Seki K. Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. Regul. Pept. 2014, 190-191:1-11. 10.1016/j.regpep.2014.04.003.
33. Paresce D., Chung H., Maxfield F. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J. Biol. Chem. 1997, 14:29390-29397.
34. Parthsarathy V., Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur. J. Pharmacol. 2013, 700(1-3):42-50. 10.1016/j.ejphar.2012.12.012.
35. Perry T., Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005, 2(3):377-385.
36. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72(5):603-612.
37. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7(9):647-940.
38. Robinson J.L., Molina-Porcel L., Corrada M.M., Raible K., Lee E.B., Lee V.M., Trojanowski J.Q. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain 2014, 137(Pt 9):2578-2587. 10.1093/brain/awu190.
39. Roy D., Chadwick K.D., Tatarkiewicz K., Lacerte C., Bergholm A.M., Brodie T., Reilly T.P. The Glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs, and monkeys. Diabetes Obes. Metab. 2014, 10.1111/dom.12294.
40. Sadry S.A., Drucker D.J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 2013, 9(7):425-433. 10.1038/nrendo.2013.47.
41. Saura C.A. Presenilin/gamma-Secretase and Inflammation. Front. Aging Neurosci. 2010, 2:16.
42. Schulz P.E., Cook E.P., Johnston D. Using paired-pulse facilitation to probe the mechanisms for long-term potentiation. J. Physiol. (Paris) 1995, 89:3-9.
43. Sharma M., Jalewa J., Holscher C. Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J. Neurochem. 2013, 128:459-471.
44. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122(4):1316-1338. 10.1172/JCI59903.
45. Talbot K., Want H.-Y., Kazi H., Bennett D., Trojanowski J.Q., Arnold S.E. The Diabetes Drug Liraglutide Ameliorates Insulin Resistance in the Hippocampal Formation of Alzheimer Disease (AD) Cases 2011, Paper presented at the AAIC, Paris.
46. Tsai M.L., Shen B., Leung L.S. Seizures induced by GABAB-receptor blockade in early-life induced long-term GABA(B) receptor hypofunction and kindling facilitation. Epilepsy Res. 2008, 79(2-3):187-200.
47. Wadden T., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., Aronne L. Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE Maintenance randomized study. Int. J. Obes. (Lond.) 2013, 37(11):1443-1451. 10.1038/ijo.2013.120.
48. Wilcock D.M., Gordon M.N., Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat. Protoc. 2006, 1(3):1591-1595.